← Eichor
Condition: Bladder Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Bladder Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial
Phase 1 · 12 location(s) · EvolveImmune United, Inc · NCT07217171A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
Phase 2 · 1 location(s) · Mayo Clinic · NCT07285044Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05621837A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767PET-imaging of Two Vartumabs in Patients With Solid Tumors
EARLY_Phase 1 · 1 location(s) · Var2 Pharmaceuticals · NCT06645808A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029A Study of VET3-TGI in Patients With Solid Tumors
Phase 1 · 7 location(s) · KaliVir Immunotherapeutics · NCT06444815A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Phase N/A · 57 location(s) · Guardant Health, Inc. · NCT05059444Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TU
NA · 2 location(s) · Azienda Ospedaliero-Universitaria di Parma · NCT07403630A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · 21 location(s) · Clasp Therapeutics, Inc. · NCT06778863TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 · 41 location(s) · Tizona Therapeutics, Inc · NCT04485013Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06041503A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.